Accordingly, IFN-active melanoma cells overexpress the multi-drug resistance pump ABCG2 and interferon-related genes (e.g., PD-L1 and HLA-A, -B, and -C), irrespective of the presence of cytokines in vitro [187], conferring a potential cross-resistance to in vivo MAPKi and immunotherapy. The gene discussed is CD274; the disease is melanoma.